Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948075 | 0.81 | TYK2 (0.35) | NFATC1GSK3BDYRK1ATYK2NTRK1 | |
| SCHEMBL21961144 | 0.79 | TYK2 (0.33) | NFATC1GSK3BDYRK1ATYK2NTRK1 | |
| SCHEMBL29736370 | 0.77 | HASPIN (0.38) | — | |
| SCHEMBL23089206 | 0.77 | HASPIN (0.38) | — | |
| SCHEMBL19131359 | 0.75 | TYK2 (0.33) | TYK2NTRK1 | |
| SCHEMBL12984352 | 0.70 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL19130911 | 0.70 | KDM4E (0.36) | DYRK1A | |
| SCHEMBL19131839 | 0.69 | CCNA2 (0.31) | DYRK1A | |
| SCHEMBL21917358 | 0.69 | DYRK1A (0.62) | NFATC1GSK3BDYRK1ANTRK1 | |
| SCHEMBL15636848 | 0.69 | NFATC1 (0.50) | NFATC1GSK3BDYRK1ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NFATC1 623/4885GSK3B 122/4885DYRK1A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.